Step 3. The third step is the phosphorylation of fructosephosphate, catalyzed by the enzyme phosphofructokinase. A second ATP molecule donates a high-energy phosphate to fructosephosphate, producing fructose-1,6- bi sphosphate. In this pathway, phosphofructokinase is a rate-limiting enzyme. This is a type of end product inhibition, since ATP is the end product of glucose catabolism. Step 4. The newly added high-energy phosphates further destabilize fructose-1,6-bisphosphate. The fourth step in glycolysis employs an enzyme, aldolase, to cleave 1,6-bisphosphate into two three-carbon isomers: dihydroxyacetone-phosphate and glyceraldehydephosphate.
Step 5. In the fifth step, an isomerase transforms the dihydroxyacetone-phosphate into its isomer, glyceraldehydephosphate. Thus, the pathway will continue with two molecules of a single isomer. At this point in the pathway, there is a net investment of energy from two ATP molecules in the breakdown of one glucose molecule. So far, glycolysis has cost the cell two ATP molecules and produced two small, three-carbon sugar molecules. Both of these molecules will proceed through the second half of the pathway, and sufficient energy will be extracted to pay back the two ATP molecules used as an initial investment and produce a profit for the cell of two additional ATP molecules and two even higher-energy NADH molecules.
Step 6. The sugar is then phosphorylated by the addition of a second phosphate group, producing 1,3-bisphosphoglycerate. Note that the second phosphate group does not require another ATP molecule.
Here again is a potential limiting factor for this pathway. If oxygen is available in the system, the NADH will be oxidized readily, though indirectly, and the high-energy electrons from the hydrogen released in this process will be used to produce ATP.
Step 7. In the seventh step, catalyzed by phosphoglycerate kinase an enzyme named for the reverse reaction , 1,3-bisphosphoglycerate donates a high-energy phosphate to ADP, forming one molecule of ATP. This is an example of substrate-level phosphorylation.
A carbonyl group on the 1,3-bisphosphoglycerate is oxidized to a carboxyl group, and 3-phosphoglycerate is formed. Step 8. In the eighth step, the remaining phosphate group in 3-phosphoglycerate moves from the third carbon to the second carbon, producing 2-phosphoglycerate an isomer of 3-phosphoglycerate. The enzyme catalyzing this step is a mutase isomerase. PK deficiency OMIM is the most common cause of nonspherocytic hemolytic anemia due to defective glycolysis and is inherited in an autosomal recessive manner.
The estimated prevalence is 51 cases ie, homozygous or compound heterozygous patients per million in the white population. Some PK-deficient patients present with hydrops fetalis.
Splenectomy often ameliorates the hemolysis, especially in severe cases, and increases reticulocyte counts even further. Persistent expression of the PK-M2 isozyme has been reported in the red blood cells of patients and animals; see below with severe PK deficiency.
By the year , more than mutations in PKLR have been reported to be associated with pyruvate kinase deficiency. In the European and North-American populations, the most frequently detected mutations are missense mutants c. There appears to be no direct relationship between the nature and location of the substituted amino acid and the type of molecular perturbation. For example, the clinical phenotype of 12 c. The causative single-base change disrupts a putative binding domain for an as-yet-unidentified trans -acting factor that mediates the effects of factors necessary for regulation of PK gene expression during red cell differentation and maturation.
PK deficiency has also been recognized in dogs and mice. In both species, the deficiency causes severe anemia and marked reticulocytosis, closely resembling human PK deficiency. Basenji dogs lack PK-R enzymatic activity as a result of a frameshift mutation. Instead, only the PK-M2 isozyme is expressed in their red blood cells. Schematic representation of the PKLR gene and its erythroid-specific promoter. Exons, but not introns, are drawn to scale.
The white rectangle represents the liver-specific exon 2. Nucleotides are numbered starting from ATG in red blood cell-specific exon 1. The locations of the more than mutations associated with PK deficiency 93 are indicated by vertical lines.
Larger vertical lines represent multiple base changes at the same nucleotide position. The horizontal lines indicate the extent of the 3 large deletions known to date. Red blood cell deficiencies of glyceraldehydephosphate dehydrogenase 98 , 99 and enolase , have been described in association with hemolytic anemia but a causal relationship was not established.
Monophosphoglycerate mutase MPGM in erythrocytes is a homodimer, composed of 2 of the ubiquitously expressed B subunits. However, neither defiency causes hemolytic anemia, despite strongly reduced enzymatic activity.
This glycolytic bypass is unique to mammalian red blood cells and represents an important physiologic means to regulate oxygen affinity of hemoglobin. Quantitatively, 2,3-DPG is the major glycolytic intermediate in the red blood cell and its levels are about equal to the sum of the other glycolytic intermediates. The increased 2,3-DPG levels result in a decreased oxygen affinity of hemoglobin so that oxygen is more readily transferred to tissue.
Thus, the anemia is ameliorated and exertional tolerance is improved. Both reactions in the Rapoport-Luebering shunt are catalyzed by the erythrocyte-specific multifunctional enzyme bisphosphoglycerate mutase BPGM , which posesses synthase formation of 2,3, BPG and phosphatase hydrolysis of 2,3-DPG to 3-phosphoglycerate activity Figure 1.
The enzyme is closely related to the glycolytic housekeeping enzyme MPGM. Instead, they presented with erythrocytosis that likely resulted from the reduced 2,3-DPG levels and, consequently, the increased oxygen affinity of hemoglobin. In addition, all family members had markedly decreased glucosephosphate dehydrogenase activity although there was no laboratory evidence of hemolysis.
DNA sequencing of the BPGM gene showed that the propositus was homozygous for a point mutation in exon 2 that predicted the substitution of Arg62 by Gln. A variety of clinical features are associated with the described hereditary enzymopathies of the red blood cell. This is mainly due to the role of the affected enzyme in glycolysis as well as the underlying molecular alteration responsible for defective enzymatic function.
Therefore, a better understanding of the clinical phenotype of defective glycolyis in the red blood cell requires knowledge regarding the genetic, biochemical, and structural consequences of mutations in the genes and the respective enzymes they encode.
However, the phenotype is not solely dependent on the molecular properties of mutant proteins but rather reflects a complex interplay between physiologic, environmental, and other genetic factors. Putative phenotypic modifiers include differences in genetic background, concomitant functional polymorphisms of other glycolytic enzymes many enzymes are regulated by their product or other metabolites , posttranslational modification, epigenetic modification, ineffective erythropoiesis, and different splenic function.
Also, aberrant enzymatic function in nonerythroid tissues may influence the clinical outcome of hereditary enzymopathies. Hence, future research aimed at the relationship between genotype and phenotype correlation in red blood cell enzymopathies will also have to take these phenotypic modifiers into account.
The authors sincerely wish to thank Gert Rijksen for helpful discussion of the manuscript. Sign In or Create an Account. Sign In. Skip Nav Destination Content Menu. Close Introduction. The Embden-Meyerhof pathway. Rapoport-Luebering shunt.
Concluding remarks. Article Navigation. The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis Richard van Wijk , Richard van Wijk. This Site. Google Scholar. Wouter W. Blood 13 : — Article history Submitted:. Cite Icon Cite. Figure 1. View large Download PPT.
Figure 2. Figure 3. Figure 4. Both authors contributed equally to the writing of the paper. The Red Blood Cell. The effect of organic phosphates from the human erythrocyte on the allosteric properties of hemoglobin.
Biochem Biophys Res Commun. Hereditary disorders of red cell enzymes in the Embden-Meyerhof pathway. Am J Hematol. Hemolytic anemias and erythrocyte enzymopathies. Ann Intern Med. The molecular biology of G6PD variants and other red cell enzyme defects. Annu Rev Med. Hereditary red cell enzymopathies. Blood Rev. The primary cause of hemolysis in enzymopathies of anaerobic glycolysis: a viewpoint.
Blood Cells. Deficiencies of glycolytic enzymes as a possible cause of hemolytic anemia. Biochim Biophys Acta. The relationship of red cell enzymes to red cell life-span.
Selectivity of proteases as a basis for tissue distribution of enzymes in hereditary deficiencies. Abnormalities of erythrocyte enzymes in dyserythropoiesis and malignancies. Clin Haematol. Disorders of erythrocyte glycolysis and nucleotide metabolism. Blood Principles and Practice of Hematology. Mammalian hexokinase 1: evolutionary conservation and structure to function analysis.
Rev Physiol Biochem Pharmacol. Evolution and regulatory role of the hexokinases. The mechanism of regulation of hexokinase: new insights from the crystal structure of recombinant human brain hexokinase complexed with glucose and glucosephosphate.
The structure of mammalian hexokinase Nat Struct Biol. An isozyme of hexokinase specific for the human red blood cell HKR. Human HKR isozyme: organization of the hexokinase I gene, the erythroid-specific promoter, and transcription initiation site. Mol Genet Metab. Identification of the cDNA for human red blood cell-specific hexokinase isozyme. Hexokinase: gene structure and mutations. Hexokinase mutations that produce nonspherocytic hemolytic anemia.
Blood Cells Mol Dis. Homozygous intragenic deletion of type I hexokinase gene causes lethal hemolytic anemia of the affected fetus [letter]. HK Utrecht: missense mutation in the active site of human hexokinase associated with hexokinase deficiency and severe nonspherocytic hemolytic anemia. Downeast anemia dea , a new mouse model of severe nonspherocytic hemolytic anemia caused by hexokinase HKI deficiency.
Single-gene disorders: what role could moonlighting enzymes play? Am J Hum Genet. Death of mouse embryos that lack a functional gene for glucose phosphate isomerase. Genet Res. The crystal structure of human phosphoglucose isomerase at 1. J Mol Biol. Human glucose phosphate isomerase: exon mapping and gene structure. Glucosephosphate isomerase deficiency. Erythrocyte enzymopathies in the newborn. Generalised glucosephosphate isomerase GPI deficiency causing haemolytic anaemia, neuromuscular symptoms and impairment of granulocytic function: a new syndrome due to a new stable GPI variant with diminished specific activity GPI Homburg.
Eur J Pediatr. Glucosephosphate isomerase deficiency associated with nonspherocytic hemolytic anemia in the mouse: an animal model for the human disease. Physical and kinetic properties of human phosphofructokinase from skeletal muscle and erythrocytes. J Biol Chem. Isozymes of human phosphofructokinase: biochemical and genetic aspects. Assignment of the human gene for muscle-type phosphofructokinase PFKM to chromosome 1 region cen leads to q32 using somatic cell hybrids and monoclonal anti-M antibody.
How do such hormones influence the use of fuel molecules by the various tissues? Demands by one cell type can be met by the consumption of its own reserves and by the uptake of fuel molecules released in the bloodstream by other cells. Energy use is tightly regulated so that the energy demands of all cells are met simultaneously. Virtually all cells respond to insulin; thus, during the fed state cell metabolism is coordinated by insulin signaling.
Figure 3: Blood glucose concentration after carbohydrate-rich and carbohydrate-poor meals. An extraordinary example is how insulin signaling rapidly stimulates glucose uptake in skeletal muscle and adipose tissue and is accomplished by the activity of GLUT4. In the absence of insulin, these transporters are located inside vesicles and thus do not contribute to glucose uptake in skeletal muscle and adipose tissue. Insulin, however, induces the movement of these transporters to the plasma membrane, increasing glucose uptake and consumption.
As different tissues continue to use glucose, the blood glucose concentration tends to reach the pre-meal concentration Figure 3. Therefore, during fasting, cell metabolism is coordinated by glucagon signaling and the lack of insulin signaling.
As a consequence, GLUT4 stays inside vesicles, and glucose uptake by both skeletal muscle cells and adipocytes is reduced. Now, with the low availability of glucose and the signals from glucagon, those cells increase their use of fatty acids as fuel molecules. Therefore, the use of fatty acids during fasting clearly contributes to the maintenance of adequate blood glucose concentration to meet the demands of cells that exclusively or primarily rely on glucose as a fuel.
But, mentioned above, glucose is used at an apparently high rate by the brain and constantly by red blood cells. And, under physiological conditions, blood glucose is maintained at a constant level, even during fasting.
How, then, is that delicate balance achieved? The liver is a very active organ that performs different vital functions.
In Greek mythology, Prometheus steals fire from Zeus and gives it to mortals. As a punishment, Zeus has part of Prometheus's liver fed to an eagle every day. Since the liver grows back, it is eaten repeatedly. This story illustrates the high proliferative rate of liver cells and the vital role of this organ for human life.
One of its most important functions is the maintenance of blood glucose. The liver releases glucose by degrading its glycogen stores. This reserve is not large, and during overnight fasting glycogen reserves fall severely. However, only the liver supplies the blood with glucose since it has an enzyme that make it possible for glucose molecules to be transported across cell membranes. Since glycogen stores are limited and are reduced within hours of fasting, and blood glucose concentration is kept within narrow limits under most physiological conditions, another mechanism must exist to supply blood glucose.
Indeed, glucose can be synthesized from amino acid molecules. This process is called de novo synthesis of glucose, or gluconeogenesis. Amino acids, while being degraded, generate several intermediates that are used by the liver to synthesize glucose Figure 2.
Alanine and glutamine are the two amino acids whose main function is to contribute to glucose synthesis by the liver. The kidneys also possess the enzymes necessary for gluconeogenesis and, during prolonged fasting, contribute to some extent to the supply of blood glucose.
Furthermore, since de novo glucose synthesis comes from amino acid degradation and the depletion of protein stores can be life-threatening, this process must be regulated. Insulin, glucagon, and another hormone, glucocorticoid, play important roles in controlling the rate of protein degradation and, therefore, the rate of glucose production by the liver. Alterations in factors that control food intake and regulate energy metabolism are related to well-known pathological conditions such as obesity, type 2 diabetes and the metabolic syndrome , and some types of cancer.
In addition, many effects and regulatory actions of well-known hormones such as insulin are still poorly understood. The consideration of adipose tissue as a dynamic and active tissue, for instance, raises several important issues regarding body weight and the control of food intake. These factors point to the importance of further studies to expand our understanding of energy metabolism, thereby improving our quality of life and achieving a comprehensive view of how the human body functions.
Cahill, G. Fuel metabolism in starvation. Annual Review of Nutrition 26 , 1—22 Iyer, A. Inflammatory lipid mediators in adipocyte function and obesity. Nature Reviews Endocrinology 6 , 71—82 Kaelin, W. Kodde, I. Metabolic and genetic regulation of cardiac energy substrate preference. Kresge, N. Otto Fritz Meyerhof and the elucidation of the glycolytic pathway. Journal of Biological Chemisry , e3 Kroemer, G. Tumor cell metabolism: Cancer's Achilles' heel.
Cancer Cell 13 , — Vander Heiden, M. Understanding the Warburg effect: The metabolic requirements of cell proliferation Science 22 , — Critical steps in cellular fatty acid uptake and utilization. Molecular and Cellular Biochemistry , 9—15 What Is a Cell? Eukaryotic Cells. Cell Energy and Cell Functions. Photosynthetic Cells. Cell Metabolism. The Origin of Mitochondria. Mitochondrial Fusion and Division. The Origin of Plastids. The Origins of Viruses.
Discovery of the Giant Mimivirus. Volvox, Chlamydomonas, and the Evolution of Multicellularity. Yeast Fermentation and the Making of Beer and Wine. Dynamic Adaptation of Nutrient Utilization in Humans.
0コメント